TARSUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.24 USD | -0.88% |
|
+3.35% | +88.84% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 839.8 | 465.2 | 391 | 670.4 | 1,445 | - | - |
| Enterprise Value (EV) 1 | 839.8 | 465.2 | 391 | 472.1 | 1,303 | 1,330 | 1,222 |
| P/E ratio | -9.57 x | -33.6 x | -5.82 x | -4.38 x | -10.1 x | -27.1 x | 15.8 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 8.16 x | 15.1 x | 38.4 x | 9.94 x | 5.54 x | 3.43 x |
| EV / Revenue | - | 8.16 x | 15.1 x | 27.1 x | 8.96 x | 5.1 x | 2.9 x |
| EV / EBITDA | -31.2 x | -39.3 x | -6.27 x | -3.32 x | -8.91 x | -18.9 x | 43.4 x |
| EV / FCF | -38,892,433 x | 147,132,296 x | - | - | - | - | - |
| FCF Yield | -0% | 0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,320 | 20,677 | 26,672 | 33,105 | 37,782 | - | - |
| Reference price 2 | 41.33 | 22.50 | 14.66 | 20.25 | 38.24 | 38.24 | 38.24 |
| Announcement Date | 3/31/21 | 3/14/22 | 3/13/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 57.03 | 25.82 | 17.45 | 145.4 | 260.7 | 421.4 |
| EBITDA 1 | -26.9 | -11.84 | -62.39 | -142.3 | -146.3 | -70.38 | 28.16 |
| EBIT 1 | -27 | -12.16 | -62.71 | -143.2 | -144.7 | -63.1 | 64.49 |
| Operating Margin | - | -21.32% | -242.92% | -820.53% | -99.51% | -24.2% | 15.3% |
| Earnings before Tax (EBT) 1 | -26.81 | -13.77 | -62.1 | -135.9 | -143.2 | -51.49 | 106.2 |
| Net income 1 | -26.81 | -13.83 | -62.09 | -135.9 | -140.5 | -51.49 | 105.7 |
| Net margin | - | -24.25% | -240.51% | -778.89% | -96.62% | -19.75% | 25.08% |
| EPS 2 | -4.320 | -0.6700 | -2.520 | -4.620 | -3.802 | -1.410 | 2.420 |
| Free Cash Flow | -21.59 | 3.162 | - | - | - | - | - |
| FCF margin | - | 5.54% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/31/21 | 3/14/22 | 3/13/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.338 | 0.539 | 15.28 | - | 10 | 2.5 | - | 1.871 | 13.08 | 27.61 | 32.43 | 39.2 | 46.11 |
| EBITDA | -14.41 | -19.48 | -5.132 | -22.81 | -14.96 | -24.85 | -32.64 | - | -44.1 | - | - | - | - |
| EBIT 1 | -14.45 | -19.52 | -5.224 | -22.91 | -15.06 | -24.95 | -32.82 | -40.94 | -44.45 | -37.68 | -36.33 | -35.14 | -34.82 |
| Operating Margin | -4,274.56% | -3,621.71% | -34.2% | - | -150.61% | -998.08% | - | -2,187.87% | -339.94% | -136.47% | -112.05% | -89.65% | -75.52% |
| Earnings before Tax (EBT) 1 | -14.8 | -20.24 | -5.743 | -22.52 | -13.6 | -23.42 | -31.42 | -39.15 | -41.9 | -35.73 | -36.68 | -36.93 | -35.15 |
| Net income 1 | -14.85 | -20.24 | -5.743 | -22.51 | -13.6 | -23.42 | -31.42 | -39.15 | -41.9 | -35.73 | -35.1 | -33.44 | -33.25 |
| Net margin | -4,393.79% | -3,754.73% | -37.59% | - | -135.99% | -936.76% | - | -2,092.36% | -320.45% | -129.39% | -108.25% | -85.32% | -72.13% |
| EPS 2 | -0.7200 | -0.9800 | -0.2400 | -0.8400 | -0.4900 | -0.8800 | -1.170 | -1.280 | -1.310 | -1.010 | -0.9900 | -0.9314 | -0.9143 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/14/22 | 5/10/22 | 8/11/22 | 11/9/22 | 3/13/23 | 5/9/23 | 8/10/23 | 11/9/23 | 2/27/24 | 5/8/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 198 | 142 | 115 | 223 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -21.6 | 3.16 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -33.5% | -8.31% | -34.5% | -69.7% | -95.9% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | -3.410 | 0.1800 | -1.990 | -4.000 | -3.290 | -1.150 | - |
| Capex | 0.46 | 0.59 | 0.51 | - | - | - | - |
| Capex / Sales | - | 1.03% | 1.96% | - | - | - | - |
| Announcement Date | 3/31/21 | 3/14/22 | 3/13/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
38.24
USD
Average target price
55.78
USD
Spread / Average Target
+45.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +88.84% | 1.46B | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- TARS Stock
- Financials Tarsus Pharmaceuticals, Inc.
